Anticipating the development of such BsAbs, targeting both EGFR and ERBB2 signaling pathways could not only synergistically inhibit tumor growth and enhance anticancer efficacy, but also effectively prevent resistance caused by mutations in either target. This evidence concerns the gene EGFR and neoplasm.